The ACS Mission Boost Grants are designed to support research projects that specifically focus on the translation to human testing. Mission Boost Grants are opportunities for independent investigators at all levels to seek additional, or "boost," resources for innovative, clinical-enabling projects. MBGs offer two stages of funding. To be considered for an MBG, research projects must focus on studies in cancer patients, such as: (1) Treatment - First Time in Humans (FTIH); clinical proof-of-concept (PoC); side effect reduction. (2) Diagnostics, Prognostics, or Medical Devices - Clinical validation in humans. (3) Prevention - Including initial incidence or recurrence in humans (biomarker based/biomarker testing) and the identification and testing of interventions. PIs are encouraged to develop collaborations with pharmaceutical companies/private entities to fully realize a project. Applicants must be an independent, full-time faculty member (or equivalent) at a not-for-profit, US-based research institution that has facilities and support to enable preclinical and clinical studies. In 2025, the requirement that MBG applicants be current or former ACS grantees or fellows was eliminated. Please visit the award's website or contact the American Cancer Society, Inc. for more information.